COMMUNIQUÉS West-GlobeNewswire

Terveystalo Plc: Lääkäriasema ILO to become a part of Terveystalo
03/04/2018
Terveystalo has acquired Lääkäriasema ILO (Juha Uusimäki Oy) on 29 March 2018. The company operates clinics in Tuuri and Vimpeli. The company's personnel will be transferred to Terveystalo as old employees and [...]
Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research Market
03/04/2018
RANCHO CORDOVA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ: KOOL ), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today [...]
ChemoCentryx to Present at Two Upcoming Investor Conferences
03/04/2018
MOUNTAIN VIEW, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI ), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor [...]
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference
03/04/2018
WARREN, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH ) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, [...]
BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
03/04/2018
BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT ) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a [...]
First Choice Healthcare Solutions Reports 2017 Results and Update on Strategic Partnership with Steward Health Care
03/04/2018
MELBOURNE, Fla., April 03, 2018 (GLOBE NEWSWIRE) -- First Choice Healthcare Solutions, Inc. (OTCQB:FCHS) ("First Choice" or the "Company"), a fully integrated, non-physician-owned, publicly traded healthcare delivery [...]
Status regarding Novo Nordisk's holding of its own shares (31 March 2018)
03/04/2018
Bagsværd, Denmark, 3 April 2018 - In continuation of the company's announcements dated 1 November 2017 and 5 February 2018 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York [...]
Treos Bio Names Gábor Illés as Its Chief Financial Officer
03/04/2018
SAN FRANCISCO and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today [...]
PositiveID Reports 2017 Results; Fourth Quarter Revenues Increase 47% Year Over Year
03/04/2018
DELRAY BEACH, Fla., April 03, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today its financial results [...]
Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma
03/04/2018
MADISON, Wis., April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted [...]
HealthEC Adds The Villages Health to Population Health Management Solution
03/04/2018
PISCATAWAY, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- HealthEC , which earned the highest overall vendor satisfaction rating in KLAS Research’s 2017 Population Health Management (PHM) Report, announced today that The [...]
Emerald Health Therapeutics Appoints Rebecca Wong as Vice President Quality Affairs
03/04/2018
VICTORIA, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”) has appointed Rebecca Wong as Vice President Quality Affairs, with responsibility for [...]
HTG Announces New Patent for Its Technology Issued in Japan
03/04/2018
Patent covers nuclease protection methods for detection of nucleotide variants TUCSON, Ariz., April 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM ), a provider of instruments, reagents, and [...]
Pediapharm Announces the Commercial Launch of Cuvposa™ in Canada
03/04/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, April 03, 2018 (GLOBE NEWSWIRE) -- Pediapharm Inc. (the “Company” or "Pediapharm") (TSX VENTURE:PDP) (OTCQB:PDDPF) is [...]
Pediapharm annonce le lancement commercial de Cuvposa(MC) au Canada
03/04/2018
N’EST PAS DESTINÉ À LA DISTRIBUTION AUX AGENCES DE PRESSE AMÉRICAINES NI À LA DIFFUSION AUX ÉTATS-UNIS MONTRÉAL, 03 avr. 2018 (GLOBE NEWSWIRE) -- Pediapharm inc. (la « Société » ou « Pediapharm ») (TSX CROISSANCE:PDP) ( [...]
Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting
03/04/2018
AUSTIN, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with [...]
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
03/04/2018
SAN DIEGO and TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO ) (TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that [...]
Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018
03/04/2018
WATERTOWN, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB ), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
03/04/2018
SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX ) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long- [...]

Pages